{"id":20754,"date":"2021-12-23T05:30:00","date_gmt":"2021-12-22T21:30:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=20754"},"modified":"2021-12-23T05:46:09","modified_gmt":"2021-12-22T21:46:09","slug":"intensive-care-med%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87-%e5%a4%9a%e8%83%bd%e6%88%90%e4%bd%93%e7%bb%84%e7%bb%86%e8%83%9e%e6%b2%bb%e7%96%97ards%e7%9a%84%e5%ae%89%e5%85%a8%e6%80%a7%e5%8f%8a%e7%96%97","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=20754","title":{"rendered":"[Intensive Care Med\u53d1\u8868\u8bba\u6587]: \u591a\u80fd\u6210\u4f53\u7ec4\u7ec6\u80de\u6cbb\u7597ARDS\u7684\u5b89\u5168\u6027\u53ca\u7597\u6548"},"content":{"rendered":"\n<ul><li>Original | Open Access | <a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00134-021-06570-4#article-info\">Published:\u00a0<time datetime=\"2021-11-23\">23 November 2021<\/time><\/a><\/li><\/ul>\n\n\n\n<h1 class=\"wp-block-heading\">Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1\/2 trial<\/h1>\n\n\n\n<h3 class=\"wp-block-heading\">G. Bellingan,\u00a0F. Jacono,\u00a0J. Bannard-Smith,\u00a0et al<\/h3>\n\n\n\n<h3 class=\"wp-block-heading\">Intensive Care Med<\/h3>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"Abs1\">Abstract<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Purpose<\/h3>\n\n\n\n<p>Bone marrow-derived, allogeneic, multipotent adult progenitor cells demonstrated safety and efficacy in preclinical models of acute respiratory distress syndrome (ARDS).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Methods<\/h3>\n\n\n\n<p>This phase 1\/2 trial evaluated the safety and tolerability of intravenous multipotent adult progenitor cells in patients with moderate-to-severe ARDS in 12 UK and USA centres. Cohorts 1 and 2 were open-label, evaluating acute safety in three subjects receiving 300 or 900 million cells, respectively. Cohort 3 was a randomised, double-blind, placebo-controlled parallel trial infusing 900 million cells (<em>n<\/em>\u2009=\u200920) or placebo (<em>n<\/em>\u2009=\u200910) within 96&nbsp;h of ARDS diagnosis. Primary outcomes were safety and tolerability. Secondary endpoints included clinical outcomes, quality of life (QoL) and plasma biomarkers.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Results<\/h3>\n\n\n\n<p>No allergic or serious adverse reactions were associated with cell therapy in any cohort. At baseline, the cohort 3 cell group had less severe hypoxia. For cohort 3, 28-day mortality was 25% for cell vs. 45% for placebo recipients. Median 28-day free from intensive care unit (ICU) and ventilator-free days in the cell vs. placebo group were 12.5 (IQR 0,18.5) vs. 4.5 (IQR 0,16.8) and 18.5 (IQR 0,22) vs. 6.5 (IQR 0,18.3), respectively. A prospectively defined severe ARDS subpopulation (PaO<sub>2<\/sub>\/FiO<sub>2<\/sub>\u2009&lt;\u2009150&nbsp;mmHg (20&nbsp;kPa);&nbsp;<em>n<\/em>\u2009=\u200916) showed similar trends in mortality, ICU-free days and ventilator-free days favouring cell therapy. Cell recipients showed greater recovery of QoL through Day 365.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/media.springernature.com\/full\/springer-static\/image\/art%3A10.1007%2Fs00134-021-06570-4\/MediaObjects\/134_2021_6570_Fig1_HTML.png?as=webp\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/media.springernature.com\/full\/springer-static\/image\/art%3A10.1007%2Fs00134-021-06570-4\/MediaObjects\/134_2021_6570_Fig2_HTML.png?as=webp\" alt=\"\"\/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">Conclusions<\/h3>\n\n\n\n<p>Multipotent adult progenitor cells were safe and well tolerated in ARDS. The clinical outcomes warrant larger trials to evaluate the therapeutic efficacy and optimal patient population.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Original | Open Access | Published:\u00a023 November 2021 Sa [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/20754"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20754"}],"version-history":[{"count":1,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/20754\/revisions"}],"predecessor-version":[{"id":20755,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/20754\/revisions\/20755"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20754"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20754"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}